key: cord-0780098-snaf9vz0
authors: Coyle, Peter V.; Chemaitelly, Hiam; Kacem, Mohamed Ali Ben Hadj; Al Molawi, Naema Hassan Abdulla; El Kahlout, Reham Awni; Gilliani, Imtiaz; Younes, Nourah; Al Anssari, Ghada Ali A.A.; Al Kanaani, Zaina; Al Khal, Abdullatif; Al Kuwari, Einas; Butt, Adeel A.; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F.; Nasrallah, Gheyath K.; Yassine, Hadi M.; Al Kuwari, Mohamed Ghaith; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H.; Bertollini, Roberto; Abu-Raddad, Laith J.
title: SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
date: 2021-05-24
journal: iScience
DOI: 10.1016/j.isci.2021.102646
sha: d2f3c37b05340f2fc578aa2e4c1ecf2b6285257a
doc_id: 780098
cord_uid: snaf9vz0

The study objective was to assess level of detectable SARS-CoV-2 antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens for 112,941 individuals (∼10% of Qatar’s urban population) attending for routine/other clinical care between May 12-September 9, 2020. Seropositivity was 13.3% (95% CI=13.1-13.6%) and was independently associated with sex, age, nationality, clinical-care encounter type, and testing date. Median optical density (antibody titer) among antibody-positive persons was 27.0 (range=1.0-150.0), with higher values associated with age, nationality, clinical-care encounter type, and testing date. Seropositivity by nationality was positively-correlated with the likelihood of having higher antibody titers (Pearson correlation coefficient=0.85; 95% CI=0.47-0.96). Less than two in every 10 individuals in Qatar’s urban population had detectable antibodies against SARS-CoV-2, suggesting this population is still far from herd immunity and at risk of subsequent infection waves. Higher antibody titer appears to be a biomarker of repeated exposures to the infection.

The study objective was to assess level of detectable SARS-CoV-2 antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens for 112,941 individuals (~10% of Qatar's urban population) attending for routine/other clinical care between May 12-September 9, 2020. Seropositivity was 13.3% (95% CI=13.1-13.6%) and was independently associated with sex, age, nationality, clinical-care encounter type, and testing date.

Median optical density (antibody titer) among antibody-positive persons was 27.0 (range=1.0-150.0), with higher values associated with age, nationality, clinical-care encounter type, and testing date. Seropositivity by nationality was positively-correlated with the likelihood of having higher antibody titers (Pearson correlation coefficient=0.85; 95% CI=0.47-0.96). Less than two in every 10 individuals in Qatar's urban population had detectable antibodies against SARS-CoV-2, suggesting this population is still far from herd immunity and at risk of subsequent infection waves. Higher antibody titer appears to be a biomarker of repeated exposures to the infection.

With the breakthrough development of highly efficacious vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Polack et al., 2020 , Voysey et al., 2020 , determining the population's cumulative infection exposure and current immunity level is critical to inform national vaccine roll-out strategies.

Qatar, located in the Arabian peninsula, with a multinational population of 2.8 million people, nearly all living in the capital city, Doha, had a significant first wave of Coronavirus Disease 2019 (COVID-19) that peaked in late May 2020 (Planning and Statistics Authority-State of Qatar, 2020, Planning and Statistics Authority-State of Qatar, 2019). As of December 23, 2020, >60,000 infections per million population (number of infections divided by total population) had been laboratory-confirmed (Hamad Medical Corporation, 2020b , Ministry of Public Health-State of Qatar, 2021). Qatar has a unique socio-demographic structure, in which single-unit and family households including children, adults and/or older adults, account for only 40% of the total population, with adults in this "urban population" often being part of the professional or service J o u r n a l P r e -p r o o f 2021a). A recently completed nationwide, population-based survey assessing "ever" infection among the CMW population found that six out of every ten persons had detectable antibodies against SARS-CoV-2 , suggesting that this population is at or near herd immunity for the variants circulating at this time , Britton et al., 2020 . In the present study, the first objective was to assess the level of infection exposure among the rest of the population of Qatar, that of the "urban population" of this country. The urban population was defined as the complement of the CMW population, that is the population that lives in single-unit or family households (not shared accommodations) and is part of the professional or service workforce. This part of the population is highly diverse and includes over 150 nationalities in addition to Qataris. The second objective was to identify predictors for infection and for having higher antibody titers.

In all, 112,941 individuals were tested for SARS-CoV-2 antibodies, representing ~10% of the urban population of Qatar (Planning and Statistics Authority-State of Qatar, 2020) (Table 1) Figure S1 of SI shows seropositivity month-by-month, which was largely stable over the study duration. There was a strong correlation between the AOR for higher antibody titers in each nationality and the corresponding SARS-CoV-2 seroprevalence of that nationality ( Figure 2 ). The Pearson correlation coefficient was 0.85 (95% CI: 0.47-0.96), possibly indicating that higher antibody titers correlate with repeated exposures to this coronavirus.

Of the 18,844 antibody-positive persons, 9,375 had a polymerase chain reaction (PCR) confirmed diagnosis prior to the antibody-positive test-47.1% (95% CI: 46.1-48.2%) (Table 3) .

Meanwhile, 1,085 of the 18,844 antibody-positive persons had or progressed to a severe infection, and 393 had or progressed to critical infection. Thus, the infection severity rate was 3.9% (95% CI: 3.7-4.2%), the infection criticality rate was 1.3% (95% CI: 1.1-1.4%), and the combined infection severity or criticality rate was 5.2% (95% CI: 4.9-5.5%). With exactly 100 COVID-19 deaths recorded among the antibody-positive persons, the infection fatality rate was 0.3% (95% CI: 0.2-0.3%).

The above results indicate that <20% of the urban population of Qatar, which constitutes ~40% of the total population and includes nearly all older adults, manifests evidence of prior infection. This seroprevalence is substantially less than that in the CMW part of the population, which was estimated recently in a nationwide survey at 55.3% , with the leading risk factor being living in a large shared accommodation , Abu-Raddad et al., 2021a .

This finding suggests that the lockdown and imposed social and physical distancing restrictions have been more successful in slowing transmission in the urban population compared to the CMW population. Building on the totality of evidence on the Qatar epidemic (Abu-Raddad et al., 2021a . Accordingly, there should exist potential for subsequent waves of infection in this part of the population, but no second wave materialized from May 2020 up to end of this year (Abu-Raddad et al., 2021a , that is before the introduction and expansion of the B.1.1.7 and B.1.351 variants of concern (Abu-Raddad et al., 2021b). On the contrary, only a slow increase in seroprevalence has occurred since the peak of the first wave (Table S2 of SI), reflecting the actual low incidence of infection in Qatar up to end of 2020 . The absence of a new wave, despite the lack of a lockdown and easing of many social distancing restrictions, may be explained by an "immunity shield" effect (Weitz et al., 2020) arising from the social mixing between the urban and CMW populations. There were significant differences in seropositivity by sex, age, and nationality. These are

probably not due to biological differences, but to differences in the likelihood of exposure to the infection. Indeed, a small proportion of the specimens tested in this study belonged to CMWs who had a higher risk of exposure to the infection than the urban population . While Hamad Medical Corporation (HMC) provides healthcare primarily to the urban population and other providers cater to the CMW population, HMC is a main tertiary care center in Qatar, and was also the nationally designated provider for COVID-19

healthcare needs. Thus, it is likely that a small proportion of specimens, which cannot be estimated precisely, was drawn from CMWs who were hospitalized for COVID-19 or other reasons. This may explain the higher antibody positivity of young Bangladeshi, Indian, and Nepalese men (Table 1) , who form the bulk of the CMW population . This may also explain the higher seroprevalence in the blood specimens drawn during inpatient or emergency clinical-care, which are more likely to be COVID-19-related, than those drawn during outpatient or home care/follow-up consultation clinical-care (Table 1 ). The higher exposure among men 20-69 years of age probably reflects their more frequent work and other activities outside the home, whereas men ≥70 years of age, urged through public-health messaging to remain at home, were more likely to do so, out of concern about infection severity.

The proportion of those antibody-positive who had a PCR-confirmed diagnosis prior to the antibody-positive test was 47.1% (Table 3) , much higher than the 9.3% in the CMW population , and that estimated for the total population of Qatar (11.6%) . This is probably because study specimens were drawn from individuals receiving healthcare, including those hospitalized for COVID-19, people more likely to have been tested for the infection. This fact, along with the difference in age structure between the urban and (Table 3 ), compared to the study of the CMW population (Al-Thani et al., 2020), or model predictions for the entire population of Qatar (Seedat et al., 2020) .

Strikingly, having a higher antibody titer varied by nationality, clinical-care type, and with time (Table 2) . Variation by nationality is probably an indirect biomarker of re-exposure to infection, J o u r n a l P r e -p r o o f resulting in repeated immune-system reactivation. This is suggested by the very strong positive correlation between the odds of having a higher antibody titer and seroprevalence across the nationalities (Figure 2 ). Lower antibody titers were found in inpatients, but this may reflect COVID-19 hospitalizations for recent infections, so that there was not sufficient time for higher antibody titers to develop. There was a trend of increasing higher antibody titers over time, which may reflect the growing pool of infected persons who have had more time to develop higher levels of detectable antibodies post-infection, or alternatively to being re-exposed to the infection.

This study has some limitations. The sample included individuals attending HMC for routine or other clinical care, but this population may not necessarily be representative of the wider urban population of Qatar. Though HMC is the main public healthcare provider and is widely accessible at minimal cost to nationals and residents, the sample may still have missed persons inclined to seek healthcare in the private sector, or who avoided contact with healthcare during the COVID-19 pandemic. Some specimens may have been drawn from CMWs, who were not part of our intended study sample. However, the large sample size, equivalent to ~10% of the urban population of Qatar, as well as the probabilistic weighting used in the analysis may have reduced inherent biases in our sample.

Laboratory methods were based on high-quality, validated commercial platforms, such as the Roche platform used for serological testing (The Roche Group, 2020, Jahrsdörfer et al., 2020).

The Roche platform is one of the most extensively used and investigated commercial platforms, with a specificity ≥99.8% (The Roche Group, 2020, Public Health England, 2020, Oved et al., 2020 ) and a sensitivity ≥89% (Jahrsdörfer et al., 2020 , Abu-Raddad et al., 2021a J o u r n a l P r e -p r o o f 2020). However, it is possible that the less-than-perfect sensitivity, especially for those with recent infections, may have underestimated the actual seroprevalence as it may take up to few weeks before recently infected individuals develop antibodies at detectable levels , Wajnberg et al., 2020 . Indeed, a recent investigation of the performance of three automated, commercial, serological platforms in Qatar, including the Roche platform, found that each of them missed ≥20% of individuals with past or current infections .

Factoring the less-than-perfect sensitivity and specificity (Sempos and Tian, 2021) would have increased the measured seroprevalence to 14.8% instead of 13.3%. The fatality rate may have been underestimated in this study as some individuals may have died before being tested, or before developing detectable antibody levels.

In conclusion, fewer than two in every 10 individuals in the urban population of Qatar had detectable antibodies against SARS-CoV-2, suggesting that this population is still well below the herd immunity threshold and is potentially at risk from a subsequent epidemic wave. This emphasizes the need to maintain current social and physical distancing restrictions while SARS-CoV-2 vaccinations are being scaled up throughout the country. The findings also suggest that higher antibody titers appear to be a biomarker of repeated exposures to the infection. 

PC conceived and designed this study and led its implementation and antibody testing. HC managed the databases, performed the statistical data analyses, and co-wrote the first draft of the manuscript. LJA led the statistical analyses and co-wrote the first draft of the article. All authors contributed to development of the study protocol, data collection, and acquisition, database development, discussions and interpretation of the results, and to the writing of the manuscript.

All authors have read and approved the final manuscript.

We declare no competing interests. Figure 2 . Adjusted odds ratios for higher antibody titers (optical densities higher than the median value of 27.0) for each nationality (Table 3) versus the corresponding SARS-CoV-2 seroprevalence for that nationality (Table 1) . J o u r n a l P r e -p r o o f Proportion of antibody-positive persons who had a prior SARS-CoV-2 PCR-confirmed diagnosis. Resource Availability

Further information and requests should be directed to Lead Contacts, Peter V. Coyle, Email:

PCoyle@hamad.qa and Laith J. Abu-Raddad, Email: lja2002@qatar-med.cornell.edu

The study did not generate new reagents.

All data are included in an aggregate form within the manuscript and its supplemental information.

A retrospective analysis of residual blood specimens collected from May 12 to September 9, 2020 was conducted to assess the level of and associations with antibody positivity in the urban population of Qatar. Residual blood specimens were collected from individuals receiving routine and other clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban population of this country and the nationally designated provider for Coronavirus

Disease 2019 (COVID-19) healthcare needs. Qatar has a universal, quality, and modern healthcare system that is heavily subsidized and equally accessible to nationals and residents.

The public healthcare system is organized into several internationally accredited entities, with HMC and the Primary Health Care Corporation (PHCC) centers typically serving the urban population, and the Qatar Red Crescent Society centers typically serving the CMW population J o u r n a l P r e -p r o o f . It follows that the tested population in this study is broadly representative of the urban population, but not of the CMW population of Qatar.

Each person in this study contributed only one antibody test, the last test performed during the study period. Antibody data generated during the study were subsequently linked to the national centralized SARS-CoV-2 polymerase chain reaction (PCR) testing and hospitalization database, which includes records for all PCR testing and COVID-19 hospitalizations in Qatar since the start of the epidemic (Hamad Medical Corporation, 2020a) . The database further includes the severity classification of hospitalized cases, based on individual chart reviews completed by trained medical personnel using the World Health Organization (WHO) criteria (World Health

Organization, 2020). The study was approved by the HMC and Weill Cornell Medicine-Qatar

Institutional Review Boards. The study was conducted following the ethics review boards guidelines and regulations.

Roche Elecsys ® Anti-SARS-CoV-2 (99.5% sensitivity (Muench et al., 2020) , 99.8% specificity tested using the AccuPower SARS-CoV-2 Real-Time RT-PCR Kit (100% sensitivity and specificity (Kubina and Dziedzic, 2020) ; Bioneer, Korea) on an ABI 7500 FAST, or loaded directly into a Roche cobas® 6800 system and assayed with the cobas® SARS-CoV-2 Test (95% sensitivity, 100% specificity (US Food and Drug Administration, 2020); Roche, Switzerland).

All laboratory testing was conducted at HMC Central Laboratory following standardized protocols.

Frequency distributions were used to describe sample characteristics and optical density among antibody-positive persons. Probability weights were applied to generate estimates representing the wider urban population. Weights were developed using population distributions by sex, age group, and nationality in the PHCC database (Primary Health Care Corporation, 2020). Since the PHCC caters mainly to the urban population of Qatar through 27 geographically-distributed centers, this database, which includes 1,468,837 registered users, describes the demographics of the urban population (Primary Health Care Corporation, 2020).

Associations with anti-SARS-CoV-2 positivity, as well as with higher antibody titers (defined as optical density higher than the median value) were investigated using chi-square tests and univariable logistic regression. Covariates with p-values ≤0.2 in univariable regression analysis were included in the multivariable model. Covariates with p-values ≤0.05 in the multivariable analysis were regarded as strong evidence for an association with the outcome. Odds ratios, adjusted ORs, 95% confidence intervals, and p-values were reported.

The antibody database was linked to the SARS-CoV-2 PCR testing and hospitalization database to enable estimation of other epidemiologic metrics. The latter included the proportion of antibody-positive persons who had a diagnosis of SARS-CoV-2 confirmed by PCR prior to the antibody test. Numbers of infections that were classified as severe, critical, or fatal, according to WHO criteria (World Health Organization, 2020), among all antibody-positive persons, were used to estimate severity, criticality, and fatality rates.

All analyses were performed in STATA/SE 16.1 (StataCorp, 2019).

J o u r n a l P r e -p r o o f

Epidemiologic characterization of introduction and expansion of the SARS-CoV-2 B

Assessment of the risk of SARS-CoV-2 reinfection

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar

How will country-based mitigation measures influence the course of the COVID-19 epidemic?

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19

A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2

Evolution and effects of COVID-19 outbreaks in care homes: a population analysis in 189 care homes in one geographical region of the UK. The Lancet Healthy Longevity

Demography, Migration, and Labour Market in Qatar

Gulf Labour Markets and Migration

Attack rates assessment of the 2009 pandemic H1N1 influenza A in children and their contacts: a systematic review and meta-analysis

SARS-CoV-2 hospitalizations and care

School closures and influenza: systematic review of epidemiological studies

Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing

High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads

Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics

Investigation of SARS-CoV-2 outbreaks in six care homes in London

Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2

Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population

Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 nonresponding seronegative subpopulation. EClinicalMedicine, 29, 100651. PLANNING AND STATISTICS AUTHORITY-STATE OF QATAR 2017. Labor force sample survey

PRIMARY HEALTH CARE CORPORATION 2020. Primary Health Care Corporation services registered users database

Population of Qatar by nationality -2019 report

Evaluation of Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates

Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error

Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

MAN0019215_TaqPathCOVID-19_CE-IVD_RT-PCR%20Kit_IFU.pdf. Accessed on December 02, 2020. US FOOD AND DRUG ADMINISTRATION 2020. Cobas® SARS-CoV-2: Qualitative assay for use on the cobas® 6800/8800 Systems

Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study

WORLD HEALTH ORGANIZATION 2020. Clinical management of COVID-19